1. Improved Post remission survival of non- favorable risk Acute Myelogenous Leukemia (AML) patients following initial remission induction therapy with FLAG+/-Idarubicin versus 3 + 7 (Anthracycline + Cytarabine). (June 2020) Authors: Solh, Melhem M; Solomon, Scott R.; Morris, Lawrence E.; Zhang, Xu; Holland, H. Kent; Bashey, Asad Journal: Leukemia research Issue: Volume 93(2020) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗